TABLE 4.
COMPARISON OF HLA-DPB1 GENOTYPE FREQUENCY, AND OF GROUPED HLA-DPB1 E69 GENOTYPE FREQUENCY, AMONG SUBJECTS WITH CHRONIC BERYLLIUM DISEASE, SUBJECTS WITH BERYLLIUM SENSITIZATION, AND CONTROL SUBJECTS
|
P Value* |
||||||
|---|---|---|---|---|---|---|
| HLA-DPB1 Genotype | Control Subjects(n = 255) | BeS(n = 70) | CBD(n = 61) | BeS versus Control Subjects | CBD versus Control Subjects | BeS versus CBD |
| A. Comparison of HLA-DPB1 Genotype Frequency among Subjects with CBD, Subjects with BeS, and Control Subjects | ||||||
| E69-containing alleles | ||||||
| a. *0201 | 67 (26.3%) | 36 (51.4%) | 21 (34.4%) | <0.0001† | 0.202 | 0.050 |
| b. *0202 | 1 (0.4%) | 2 (2.9%) | 3 (4.9%) | 0.118 | 0.024 | 0.663 |
| c. *0601 | 3 (1.2%) | 9 (12.9%) | 11 (18.0%) | <0.0001† | <0.0001† | 0.411 |
| d. *0801 | 0 (0) | 1 (1.4%) | 0 (0) | 0.215 | n/a | 1.0 |
| e. *0901 | 2 (0.8%) | 4 (5.7%) | 4 (6.6%) | 0.021 | 0.014 | 1.0 |
| f. *1001 | 11 (4.3%) | 9 (14.8%) | 9 (12.9%) | 0.020 | 0.006 | 0.753 |
| g. *1301 | 14 (5.5%) | 7 (10.0%) | 5 (8.2%) | 0.177 | 0.382 | 0.721 |
| h. *1601 | 1 (0.4%) | 3 (4.3%) | 2 (2.9%) | 0.033 | 0.096 | 1.0 |
| i. *1701 | 4 (1.6%) | 7 (11.5%) | 7 (10.0%) | 0.003 | 0.001 | 0.785 |
| j. *1901 | 1 (0.4%) | 0 (0%) | 0 (0%) | 1.0 | 1.0 | n/a |
| Non–E69-containing alleles | ||||||
| k. *0101 | 20 (7.8%) | 7 (10.0%) | 5 (8.2%) | 0.562 | 1.0 | 0.721 |
| l. *0301 | 37 (14.5%) | 6 (8.6%) | 6 (9.8%) | 0.194 | 0.339 | 0.802 |
| m. *0401 | 187 (73.3%) | 35 (50.0%) | 26 (42.6%) | 0.0002† | <0.0001† | 0.398 |
| n. *0402 | 62 (24.3%) | 2 (2.9%) | 9 (14.8%) | <0.0001† | 0.108 | 0.014 |
| o. *0501 | 6 (2.3%) | 1 (1.4%) | 3 (4.9%) | 1.0 | 0.383 | 0.338 |
| p. *1101 | 8 (3.1%) | 1 (1.4%) | 2 (3.3%) | 0.690 | 1.0 | 0.598 |
| q. *1401 | 10 (3.9%) | 2 (2.9%) | 1 (1.6%) | 1.0 | 0.698 | 1.0 |
| r. *1501 | 1 (0.4%) | 1 (1.4%) | 0 (0%) | 0.385 | 1.0 | 1.0 |
| s. *2001 | 3 (1.2%) | 0 (0%) | 0 (0%) | 1.0 | 1.0 | n/a |
| t. *2301 | 2 (0.8%) | 0 (0%) | 0 (0%) | 1.0 | 1.0 | n/a |
| B. Comparison of Grouped HLA-DPB1 E69 Genotype Frequency among Subjects with CBD, Subjects with BeS, and Control Subjects | ||||||
| Any E69+ (one or two copies) | 97 (38.0%) | 65 (92.9%) | 51 (83.6%) | <0.0001† | <0.0001† | 0.097 |
| Any *02 (one or two copies) | 68 (26.7%) | 37 (52.9%) | 24 (39.3%) | <0.0001† | 0.050 | 0.122 |
| Single *02 with non-E69 | 57 (22.3%) | 21 (30.0%) | 13 (21.3%) | 0.184 | 0.850 | 0.258 |
| Any non-*02 E69+ (one or two copies) | 36 (14.1%) | 39 (55.7%) | 37 (60.7%) | <0.0001† | <0.0001† | 0.568 |
| Single E69+ non*02 with non-E69 | 29 (11.4%) | 26 (37.1%) | 26 (42.6%) | <0.0001† | <0.0001† | 0.522 |
| Any two E69+ copies | 11 (4.3%) | 18 (25.7%) | 12 (19.7%) | <0.0001† | <0.0001† | 0.412 |
| Two E69+ copies (*02 alleles) | 4 (1.6%) | 5 (7.1%) | 1 (1.6%) | 0.025 | 1.0 | 0.214 |
| Two E69+ copies (*02 plus non-*02) | 7 (2.75%) | 11 (15.7%) | 10 (16.4%) | 0.0002† | 0.0002† | 0.916 |
| Two E69+ copies (non-*02 alleles) | 0 (0%) | 2 (2.9%) | 1 (1.6%) | 0.046 | 0.193 | 1.0 |
Definition of abbreviations: BeS = beryllium sensitivity; CBD = chronic beryllium disease; n/a = not applicable, analysis not possible.
*
Compared by chi-square or Fisher's exact method; unadjusted P values reported.
†
Significant after Bonferroni correction (n = 87), α = 0.0006.